Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...

Last week, you might have seen that Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) released its yearly result to ...

Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective hoisted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports.

Ultragenyx has demonstrated solid financial performance in recent quarters, beating revenue expectations and raising guidance. In its most recent quarter, the company reported revenue of $147 ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

A robotic device developed by University of Utah engineers allows eye surgeons to perform high-precision procedures on the retina, the fragile lining on the back of the eye that is less than a ...

Just days after settling with Thermo Fisher for an undisclosed sum, the family of Henrietta Lacks has filed a lawsuit against Ultragenyx, another US biotech that it accuses of profiting from cells ...